![Bitcoin price today: flat at $67k as rate fears favor dollar](https://i-invdn-com.investing.com/news/moved_small-LYNXMPEI850WX_L.jpg)
Please try another search
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. As of June 11, 2024, Deciphera Pharmaceuticals, Inc. operates as a subsidiary of Ono Pharmaceutical Co., Ltd.
Name | Age | Since | Title |
---|---|---|---|
John de Groot | - | - | Member of Scientific Advisory Board |
Filip Janku | 50 | 2015 | Member of Scientific Advisory Board |
Michele De Palma | - | - | Member of Scientific Advisory Board |
Jean-Yves Blay | 62 | 2015 | Member of Scientific Advisory Board |
John S. Condeelis | - | - | Member of Scientific Advisory Board |
F. Stephen Hodi | - | 2015 | Member of Scientific Advisory Board |
Steven L. Hoerter | 53 | 2018 | President, CEO & Director |
Toichi Takino | 56 | 2024 | Director |
Masayuki Tanigawa | - | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review